



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



CZC-54252

Item No. 17998

CAS Registry No.: 1191911-27-9

Formal Name: N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-methanesulfonamide

MF: C₂₂H₂₅ClN₆O₄S

FW: 505.0


Purity: ≥98%

UV/Vis.: λ_{max}: 282 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

CZC-54252 is supplied as a crystalline solid. A stock solution may be made by dissolving the CZC-54252 in the solvent of choice. CZC-54252 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CZC-54252 in these solvents is approximately 10 and 20 mg/ml, respectively.

CZC-54252 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CZC-54252 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CZC-54252 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CZC-54252 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2; IC₅₀s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively).¹ It has been shown to protect against neuronal injury induced by Parkinson's disease-related LRRK2-G2019S mutant activity in primary human neurons with an EC₅₀ value of 1 nM.²

References

1. Kramer, T.T., Monte, F.L., Göring, S., *et al.* Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. *ACS Chem. Neurosci.* **3**(3), 151-160 (2012).
2. Ramsden, N.G., Perrin, J., Ren, Z., *et al.* Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. *ACS Chem Biol.* **6**(10), 1021-1028 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM